Despite disappointing results from the initial clinical trials, the death ligand TRAIL remains a promising candidate for use in anti-cancer therapies, as it is able to trigger cancer cell death through its two apoptosis-inducing receptors, TRAIL-R1 and TRAIL-R2 [34,41]. Here, TNFSF10 is linked to cancer.